CGON Stock Forecast & Price Target

CG Oncology is supported by a differentiated intravesical oncolytic immunotherapy with a clean safety profile and strong clinical validation, highlighted by a 76% complete response rate in interim Phase III BOND-003 Cohort C and an 83% complete response rate in Phase II CORE-001 with Keytruda. The company’s outlook is further strengthened by PIVOT-006 topline data expected in the near-term, with the vast majority of target events accrued, and by a BLA that remains on track for completion in 4Q26, supporting a potential approval and $38M in revenues in '27. Beyond the lead program, expansion into intermediate-risk and other NMIBC settings, plus encouraging CORE-008 Cohort CX results showing 96.0% HG-EFS at 3 months and 89.5% at 6 months, broadens the addressable market and reinforces the long-term commercial opportunity.

CG Oncology is vulnerable to a negative outlook because its value depends almost entirely on cretostimogene grenadenorepvec, creating significant single-asset concentration risk if either of the two phase three trials or the phase two checkpoint inhibitor study disappoint. The investment case is further weakened by the possibility of delays to approval, which could pressure the share price, while competition from commercial and development-stage companies with greater R&D and commercial resources may limit adoption in similar bladder-cancer indications. Financially, the company may need additional equity financing through a secondary offering to complete development, and the market opportunity itself is challenged by outsized share accrual from TAR-200 potentially driven by reimbursement dynamics.